ArticleAnais brasileiros de dermatologia
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Differential associations of IgG-aFcεRI and IgG-aIgE autoantibodies with clinical phenotypes of type IIb chronic spontaneous urticaria.The World Allergy Organization journal · 2026Article
- Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms.Asia Pacific allergy · 2026Review
- Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Early control or gradual relief? Gender-specific real-world insights into omalizumab response in chronic spontaneous urticaria patients.The World Allergy Organization journal · 2026Article
- Predictors of early treatment response to antihistamines and omalizumab in chronic spontaneous urticaria.Frontiers in allergy · 2025Review
- Clinical and molecular aspects of managing chronic spontaneous urticaria: identifying endotypes, phenotypes, and determinants of treatment response and resistance.Frontiers in allergy · 2025Review
- Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Is there a difference between women and men in chronic spontaneous urticaria? A systematic review on gender and sex differences in CSU patients.The World Allergy Organization journal · 2024Review
- A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria.Dermatology and therapy · 2024Review
- In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria.Clinical and translational allergy · 2023Article
- Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.
objectiveTo determine indicators of response to Oma or Cs-A in CSU patients.
methodsWe retrospectively analyzed data from seven centers in Turkey; the inclusion criteria for patients were to receive both Oma and Cs-A treatment (not concurrently) at some point in time during their follow-up. Clinical and laboratory features were compared between groups.
resultsAmong 110 CSU patients; 47 (42.7%) were Oma-responders, 15 (13.6%) were Cs-A-responders, and 24 (21.8%) were both Oma and Cs-A responders and 24 (21.8%) were non-responders to either drug. High CRP levels were more frequent in Cs-A-responders (72.7% vs. 40.3%; p = 0.055). Oma-responders had higher baseline UCT (Urticaria Control Test) scores (6 vs. 4.5; p = 0.045). Responders to both drugs had less angioedema and higher baseline UCT scores compared to other groups (33.3% vs. 62.8%; p = 0.01 and 8 vs. 5; p = 0.017). Non-responders to both drugs had an increased frequency in the female gender and lower baseline UCT scores compared to other groups (87.5% vs. 61.6%; p = 0.017 and 5 vs. 7; p = 0.06). STUDY LIMITATIONS: Retrospective nature, limited number of patients, no control group, the lack of the basophil activation (BAT) or BHRA (basophil histamine release assay) tests.
conclusionsBaseline disease activity assessment, which considers the presence of angioedema and disease activity scores, gender, and CRP levels might be helpful to predict treatment outcomes in CSU patients and to choose the right treatment for each patient. Categorizing patients into particular endotypes could provide treatment optimization and increase treatment success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.